Schedule 13D/G History
Ownership

James E. Flynn - Significant Ownership

Signature - Title: James E. Flynn - Jonathan Isler, Attorney-in-Fact
Location: New York, NY
Summary: This page shows a list of all the recent SCHEDULE 13D/G filings made by James E. Flynn.

Significant Ownership of James E. Flynn

Sym	Company	Class	Ownership	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
OMIC	Singular Genomics Systems, Inc.	Common Stock, par value $0.0001 per share	100%	$20K	-$4.97M	1K	-99.6%	Deerfield Mgmt IV, L.P.	Feb 21, 2025
NUVL	Nuvalent, Inc.	Class A common stock, $0.0001 par value per share	27.59%	$1.76B		23.6M		Deerfield Management Company, L.P.	Dec 31, 2024
SPRY	ARS Pharmaceuticals, Inc.	Common Stock, par value $0.0001 per share	10.72%	$126M		10.5M		Deerfield Management Company, L.P.	Mar 20, 2025
PHGE	BiomX Inc.	Common Stock, par value $0.0001 per share	9.99%	$2.18M		15.6M		Deerfield Management Company, L.P.	Feb 27, 2025
AFIB	Acutus Medical, Inc.	Common Stock, par value $0.001 per share	9.1%	$275K		5.49M		James E. Flynn	Jan 27, 2025
INDV	Indivior PLC	Ordinary Shares, $0.50 nominal value per share	7.16%	$86.7M		8.88M		Deerfield Mgmt, L.P.	Dec 31, 2024
DCGO	DocGo Inc.	Common Stock	4.95%	$15.3M		5.05M		Deerfield Mgmt, L.P.	Feb 13, 2025
ALHC	Alignment Healthcare, Inc.	Common Stock	3.81%	$110M		7.3M		Deerfield Mgmt, L.P.	Dec 31, 2024
CPRX	Catalyst Pharmaceuticals, Inc.	Common Stock	2.63%	$66.4M		3.13M		Deerfield Mgmt, L.P.	Dec 31, 2024
VTYX	Ventyx Biosciences, Inc.	Common Stock	0.76%	$765K		535K		Deerfield Mgmt, L.P.	Dec 31, 2024
KURA	Kura Oncology, Inc.	Common Stock	0%	$0		0		Deerfield Mgmt, L.P.	Dec 31, 2024
PRLD	Prelude Therapeutics Incorporated	Common Stock	0%	$0		0		Deerfield Mgmt, L.P.	Dec 31, 2024

Showing 1 to 12 of 12 entries

Schedules 13D/G Reported by James E. Flynn:

Showing 0 to 0 of 0 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.